Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes

Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

The C-shaped meniscus cartilages normally insert into bone around the tibial spines of the knee. As the knee joint rotates and flexes, circumferential hoop stresses are generated within the tissue, resisted by the collagen fibers that define both the insertion points and the ultrastructure of the meniscus tissue itself. For a transplanted meniscus to work normally, the biomechanical interface of the collagen fibers to the bone must be recreated.
Source: Arthroscopy - Journal of Arthroscopic and Related Surgery - Category: Surgery Authors: Tags: Editorial Commentary Source Type: research
The causes of graft extrusion after lateral meniscus allograft transplantation seem to be a multifactorial problem. A recent study shows that the lateral capsulodesis technique could result in better results relative to the degree of meniscal extrusion compared with the bone-bridge fixation technique. Long-term comparative clinical studies are needed to confirm the efficacy of this procedure.
Source: Arthroscopy - Journal of Arthroscopic and Related Surgery - Category: Surgery Authors: Tags: Editorial Commentary Source Type: research
Meniscal allograft transplantation (MAT) is an established treatment for a symptomatic, meniscus-deficient knee. It is well known that MAT is effective in patients with good cartilage even in the early era of this procedure. The role of MAT in arthritic knees is getting more and more clear with increasing evidence over the last decade. Now we are able to expand our surgical indication to arthritic patients and provide them with individualized explanation for outcome and survival.
Source: Arthroscopy - Journal of Arthroscopic and Related Surgery - Category: Surgery Authors: Tags: Editorial Commentary Source Type: research
CONCLUSION: In this group of GPs, participation rates were high for most of the therapeutic and communicative tasks suggested in the questionnaire. GP participation is feasible not only in palliative care, but also in some aspects of oncological treatment and in clinical follow-up. Communication with both patient and hospital seemed good in this local setting. GPs are important helpers for some cancer patients. PMID: 29788744 [PubMed - in process]
Source: Rural and Remote Health - Category: Rural Health Tags: Rural Remote Health Source Type: research
Clovis Chabert, Camille Laporte, Arnold Fertin, Emily Tubbs, C écile Cottet-Rousselle, Florence Rivera, Magali Orhant-Prioux, Anaick Moisan, Eric Fontaine, Pierre-Yves Benhamou, Sandrine Lablanche
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions PET/CT compared to CECT allowed a more accurate staging and after therapy pointed out minimal residual disease in 22% of CECT negative pts and complete remission in 36% of CECT positive pts.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: MTA I: Leukemia/Lymphoma/Myeloma Posters Source Type: research
Conclusion Most PTCL relapses were detected before planned SI, and most patients had symptoms with relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse, suggesting a limited utility of routine imaging for detecting PTCL relapses. Micro-Abstract Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. The present study of patients with peripheral T-cell lymphoma showed similar data, with most relapses detected apart from planned SI and associated with abnormal symptoms or signs...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions The majority of PTCL relapses were detected prior to planned SI and most patients had symptoms on relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse suggesting a limited utility of routine imaging in detecting PTCL relapses. Teaser Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. This study in patients with peripheral T-cell lymphoma (PTCL) is similar in that it showed that most relapses are detected apart from planned SI and are associated with abnormal s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion SS is a rare and aggressive type of CTCL that is refractory to current therapies. We report that CRs can be achieved in 3 methods: combined immunomodulatory therapy, targeted biologic agents, or total skin electron beams followed by nonablative allogeneic SCT. Micro-Abstract Sézary syndrome is a rare leukemic variant of primary cutaneous non-Hodgkin lymphomas that is difficult to treat. We report on 18 patients who had achieved long-term complete remission or response (CR) of ≥ 1 year and 7 patients who had achieved durable responses (DR) with subsequent relapse. The choices of therapy, including...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants | USA Health